{"title": "USDA grants license approval for Circumvent CML vaccine for pigs", "author": "Dvm", "url": "https://www.dvm360.com/view/usda-grants-license-approval-for-circumvent-cml-vaccine-for-pigs", "hostname": "dvm360.com", "description": "Merck claims the vaccine is effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, 3 weeks of age and older", "sitename": "DVM 360", "date": "2022-06-08", "cleaned_text": "Merck claims the vaccine is effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, 3 weeks of age and older Merck Animal Health announced today that it has received license approval in the US from the Department of Agriculture (USDA) for its Circumvent CML vaccine. Merck issued a press release that claims Circumvent CML is the first-ready-to-use, single-dose vaccine effective against disease and 2d, Mycoplasma hyopneumoniae, and in pigs, 3 weeks of age or older.1 The Circumvent CML product label provided by Merck additionally claims that the duration of immunity for Porcine Circovirus Type 2d is at least 16 weeks, the duration for immunity for Mycoplasma hyopneumoniae is at least 10 weeks, and the Duration of immunity for ileitis due to Lawsonia intracellularis is at least 20 weeks. However, the duration of immunity for Porcine Circovirus Type 2a has not been established.2 \"Merck Animal Health is excited to bring this important innovation to our customers as part of our commitment to offering comprehensive solutions for improved animal health outcomes,\" said Jamie Lehman, DVM, swine technical services veterinarian at Merck Animal Health. \"This vaccine nicely complements Circumvent PCV G2, PCV-M G2, and Porcilis Ileitis product portfolio, providing swine veterinarians and producers the additional option of vaccinating against disease caused by PCV2, Mycoplasma hyopneumoniae, and Lawsonia intracellularis all in 1 bottle.\" says Circumvent CML will be available in 50-ml, 250-ml, and eventually, 500-ml dose presentations, beginning in early 2023. References "}